Certain Warrants of Tactile Systems Technology, Inc. are subject to a Lock-Up Agreement Ending on 23-JAN-2017.
January 22, 2017
Share
Certain Warrants of Tactile Systems Technology, Inc. are subject to a Lock-Up Agreement Ending on 23-JAN-2017. These Warrants will be under lockup for 180 days starting from 27-JUL-2016 to 23-JAN-2017.
Details:
The executive officers, directors, substantially all of company's other stockholders, option holders, and warrant holders have agreed that they will not offer, pledge, announce the intention to sell, sell or contract to sell any shares of its common stock, sell any option or contract to purchase any shares of its common stock, purchase any option or contract to sell any shares of its common stock, grant any option, right or warrant to purchase any shares of its common stock, make any short sale or otherwise transfer or dispose of any shares of its common stock, enter into any swap or other agreement that transfers, in whole or in part, the economic consequences of ownership of any shares of its common stock whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise, or demand that company file a registration statement related to its common stock for a period of 180 days, after the date of the prospectus without the prior written consent of Piper Jaffray & Co. and William Blair & Company, L.L.C.
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company providing therapies for people with chronic disorders. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The Company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The Company's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.